scholarly journals Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Yuh-Shyan Tsai ◽  
Hong-Lin Cheng ◽  
Tzong-Shin Tzai ◽  
Nan-Haw Chow
Keyword(s):  
Bladder Cancer ◽  
Clinical Trials ◽  
Urothelial Carcinoma ◽  
Cox Regression ◽  
Meta Analysis ◽  
Expression Patterns ◽  
Receptor Expression ◽  
Erbb Receptor ◽  
Erbb Receptor Family ◽  
Receptor Family

The prognostic importance of examining ErbB receptor family expression in human bladder cancer remains uncertain. Using published evidence, we examined the clinical value and the updated results of clinical trials targeting ErbB receptor family members. Twenty-seven articles from 65 references related to ErbB receptor expression assessment in bladder cancer were reviewed. The estimates included the association significance, hazard ratios, and 95% confidence intervals (CIs) from actuarial curves and survival analyses. A meta-analysis was done on those reports using univariate log-rank tests or a Cox-regression model. The methods of analysis and study subjects chosen varied widely among studies. The overall risks of disease progression for patients with EGFR or ErbB2 overexpression were 4.5 (95% CI: 2.5–8.4) and 1.1 (95% CI: 0.6–1.9), and the risks of mortality were 3.0 (95% CI: 1.6–5.9) and 1.1 (95% CI: 1.0–1.2), respectively. However, the significance of coexpression patterns of the ErbB receptor family remains controversial. None of six clinical trials yielded convincing results for blockading ErbB receptor signaling in urothelial carcinoma. The results of this analysis suggest that assessing co-expression patterns of the ErbB family may provide better prognostic information for bladder cancer patients.

Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma

1997 ◽  
Vol 430 (6) ◽  
pp. 461-466 ◽  
Author(s):  
N.-H. Chow ◽  
Hsiao-Sheng Liu ◽  
Hsiao-Bai Yang ◽  
Shih-Huang Chan ◽  
Ih-Jen Su
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Expression Patterns ◽  
Transitional Cell ◽  
Erbb Receptor ◽  
Erbb Receptor Family ◽  
Normal Urothelium ◽  
Receptor Family

erbB receptor expression patterns in human bladder cancer

Urology ◽  
2005 ◽  
Vol 66 (1) ◽  
pp. 196-200 ◽  
Author(s):  
P.H. Rajjayabun ◽  
P.E. Keegan ◽  
J. Lunec ◽  
J.K. Mellon
Keyword(s):  
Bladder Cancer ◽  
Expression Patterns ◽  
Receptor Expression ◽  
Erbb Receptor ◽  
Human Bladder Cancer ◽  
Human Bladder

Impact of clinicopathological features on survival in patients treated with immune-based combinations for metastatic urothelial carcinoma: A meta-analysis of randomized clinical trials.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16534-e16534
Author(s):  
Veronica Mollica ◽  
Alessandro Rizzo ◽  
Matteo Santoni ◽  
Andrea Marchetti ◽  
Matteo Rosellini ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Liver Metastases ◽  
Urothelial Carcinoma ◽  
Meta Analysis ◽  
Clinicopathological Features ◽  
Cochrane Library ◽  
Risk Of Death ◽  
Metastatic Urothelial Carcinoma ◽  
Ecog Ps ◽  
The Impact

e16534 Background: Immune checkpoint inhibitors (ICIs) have recently revolutionized the treatment landscape of metastatic urothelial carcinoma (mUC). Nonetheless, little is known regarding the impact of clinicopathological features in this setting. We performed a meta-analysis aiming to evaluate the predictive value of ECOG-PS, age, gender, liver metastases, and histology in randomized controlled trials (RCTs) comparing ICI-based combinations versus chemotherapy in mUC patients. Methods: We retrieved all the relevant RCTs through PubMed/Med, Cochrane library, and EMBASE; additionally, proceedings of the main international oncological meetings were also searched for relevant abstracts. Eligible studies included RCTs comparing ICI-based combinations versus chemotherapy alone in mUC patients. The primary endpoint was overall survival (OS), measured as hazard ratio (HR) with corresponding 95% confidence interval (CI). All statistical analyses were performed using R studio software. Results: Overall, 1032 mUC patients were included in the analysis. Compared with chemotherapy, ICI-based combinations significantly decreased the risk of death in several clinicopathological subgroups, including no liver metastases (HR, 0.84; 95% CI, 0.74-0.95) and ECOG-PS 0 patients (HR, 0.84; 95% CI, 0.72-0.97). Similarly, ICI-based combinations were associated with prolonged OS in mUC patients who were < 65 years old (HR, 0.82; 95% CI, 0.72-0.95), as well as in male (HR, 0.90; 95% CI, 0.82-0.99) and female patients (HR, 0.81; 95% CI, 0.68-0.97). Conversely, a non-statistically significant benefit was observed for chemotherapy alone in mUC patients with liver metastases (HR, 1.06; 95% CI, 0.86-1.31). Conclusions: According to our results, the magnitude of benefit of ICI-based combinations over chemotherapy in mUC was consistent across a number of clinicopathological subgroups, while a proportion of patients could respond to chemotherapy alone.Despite several limitations affect our analysis, we believe these results could guide in everyday treatment decision-making, also assisting in the design and interpretation of future clinical trials on ICIs in mUC.

Frequent overexpression of ErbB - receptor family members in brain metastases of non-small cell lung cancer patients

Apmis ◽  
2013 ◽  
Vol 121 (12) ◽  
pp. 1144-1152 ◽  
Author(s):  
Anna Sophie Berghoff ◽  
Manuel Magerle ◽  
Ayseguel Ilhan-Mutlu ◽  
Carina Dinhof ◽  
Georg Widhalm ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Small Cell ◽  
Erbb Receptor ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Erbb Receptor Family ◽  
Receptor Family

Contemporary utilization trends and survival outcomes in patients undergoing radical cystectomy and bladder preservation therapy for muscle invasive bladder cancer.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 387-387
Author(s):  
David Cahn ◽  
Elizabeth Handorf ◽  
Michael Nordsiek ◽  
Thomas M. Churilla ◽  
Eric M. Horwitz ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Radical Cystectomy ◽  
Selection Criteria ◽  
Cox Regression ◽  
External Beam Radiotherapy ◽  
Stage Ii ◽  
Bladder Preservation ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

387 Background: To compare overall survival (OS) in patients undergoing radical cystectomy (RC) and bladder preservation therapy (BPT) for muscle invasive urothelial carcinoma of the bladder. Methods: We conducted a retrospective, observational cohort study in which we reviewed the National Cancer Database (NCDB) to identify patients with analytic stage II-III (N0M0) urothelial carcinoma of the bladder from 2003-2011. BPT patients were stratified as any external beam radiotherapy (EBRT), definitive radiotherapy (RT) [50-80Gy], and definitive RT + chemotherapy. Treatment trends were evaluated using Pearson Chi-square tests. OS was compared between RC and BPT using unadjusted Kaplan Meier curves and Cox regression models adjusted for year of treatment, hospital volume, and patient/tumor characteristics using increasingly stringent selection criteria to identify those undergoing BPT. Results: Of the 603,298 patients with bladder cancer captured in the NCDB from 2003-2011, 9% (n = 54,518) had analytic stage II-III with urothelial histology. 51.1% (n = 27,843) of these patients were treated with RC (70.9%, n = 19,745) or BPT (29.1%, n = 8,098). Of the patients undergoing BPT, stratified by selection criteria, 26.9% (n = 2,176) and 15.0% (n = 1,215) were treated with definitive RT and definitive RT + chemotherapy, respectively. Following adjustment, improved survival in patients undergoing RC was noted regardless of BPT definition employed in multivariate analysis. However, we noted attenuated differences in OS using increasingly stringent definitions for BPT (EBRT: HR 2.2 [CI 2.15-2.29]; definitive RT: HR 1.94 [CI 1.74-2.14]; definitive RT + chemotherapy: HR 1.56 [CI 1.45-1.68]). Conclusions: In the NCDB, receipt of BPT was associated with decreased OS compared to RC in all patients with stage II-III urothelial carcinoma, in part due to selection biases. However, the use of increasingly stringent definitions of BPT attenuated the observed survival differences. Further randomized prospective controlled trials are needed to compare trimodal BPT to RC to identify optimal candidates for bladder preservation.

Sign in / Sign up

Export Citation Format

Share Document